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INTRODUCTION
Meniere’s disease is characterized by rotatory vertigo, hearing loss, tinnitus, and fullness of the ear.  Its prevalence has been estimat-
ed as 190/100,000 in the American population [1]. Most of the patients respond to medical treatment. Intratympanic (IT) treatment 
options are good alternatives in patients that do not respond to medical treatment. It has been shown that medications admin-
istered into the middle ear pass into the inner ear through oval and round windows, in very high concentrations [2]. IT gentamicin 
application has been widely accepted in Meniere’s disease because of the dominant vestibulotoxic effect of the agent [3, 4]. The 
mechanism of action has been supposed to be destruction of the dark cells to decrease endolymph secretion and /or vestibular 
sensory cells, and a reduction in the sensation of vertigo [5, 6]. In addition to its effects on the target organ, gentamicin may exert a 
toxic effect on the cochlear sensory cells, also. The rate of hearing loss has been reported between 0% and 75% in clinical IT appli-
cations, depending on the dose and frequency of application [7].
A number of methods have been employed to make IT gentamicin application more safer and manageable. A piece of gelfoam 
soaked in gentamicin was directly put on the round window in order to standardize the dose and duration of the agent given [8]. 
Some others covered the round window with connective tissue, then administered IT gentamicin[9, 10]. The agent was administered 
together with dexamethasone in order to decrease harmful effects of the aminoglycosides [4]. It was speculated that the toxic effects 
of the aminoglycosides could be prevented in this way. 
Despite all those efforts, IT gentamicin application still carries the risk for hearing loss. A new method is needed in which vertigo is 
prevented and hearing is preserved with only a single intervention.  
Selective Window Application of Gentamicin+ 
Dexamethasone in Meniere's Disease
OBJECTIVE: The purpose of the study is to prevent hearing loss when using intratympanic (IT) gentamicin for intractable Meniere’s disease. 
MATERIALS and METHODS: It is a retrospective case review study. Twenty five patients who had definite Meniere’s disease and had either selec-
tive window application or weekly IT gentamicin were included into the study. First group (selective) had dexamethasone on the round window 
and gentamicin on oval window during exploratory tympanotomy procedure. The second group had IT gentamicin at weekly intervals. The de-
gree of caloric weakness (CW), average hearing level in low pitch (HLP) (250, 500, 1000, 2000 Hz) and high pitch (HHP) (4000, 6000, 8000 Hz) were 
compared before and after treatment. The need for further treatment was noted.
RESULTS: In the first group, the average HLP was increased from 51.6±7dB to 52.2±5.6 dB. The average HHP was increased 41.96±20.2 dB to 
47.2±18.3 dB after treatment.  The CW changed from 37.6±23.9 % to 54.6±30.6 %. In the second group, the average HLP was increased from 
56.3±10.5 dB to 61.65±18.3 dB. The average HHP was increased 59.05±17.4 dB to 69.4±21.98 dB after treatment.  The CW changed from 45.8±22.3% 
to 71.53±29.63 %. Both methods had statisticaly significant increase in caloric weakness. But only IT gentamicin led a significant hearing loss in 
HHP. 
CONCLUSION: The use of dexamethasone and gentamycin via different windows in the middle ear is safe and effective method for Meniere’s 
disease in the short term. Application of dexamethasone protects not only the hearing cells but vestibular cells also.
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A new application was planned to administer gentamicin with dexa-
methasone to decrease the risk for hearing loss, since it has been 
known that dexamethasone prevents reactions causing cell death. 
However, administration of two drugs simultaneously into the mid-
dle ear would cause a decrease in the vestibulotoxic effect. Therefore, 
we planned to control absorption of the agents from the oval and 
round windows. Oval and round windows were used for application 
of dexamethasone and gentamicin separately but at the same time. 
The results were compared with control group treated with weekly 
administration of IT gentamicin. 
MATERIALS and METHODS
In this study, we retrospectively analyzed the files of 25 patients with 
definite Meniere’s disease, who had IT gentamicin with two different 
methods. Patients selected the method according to their will, after 
we explained the situation and all possible side effects. All had signed 
an informed consent about the procedure. Meniere’s disease was di-
agnosed according to the 1995 diagnostic criteria of American Acad-
emy of Otorhinolaryngology. The ethical approval of the study was 
obtained from the institutional committee (No:60116787-020/37).
The patients who had been followed up in the “vertigo outpatient 
clinic” for a long time had had complete blood count, pure tone au-
diogram, vestibule-ocular tests, vestibulospinal tests, and caloric test 
on their admission. On follow up, their audiograms repeated time to 
time. Temporal magnetic resonance imaging was obtained for differ-
ential diagnosis in patients with unilateral hearing loss. 
Intratympanic T gentamicin was administered to the patients diag-
nosed with Meniere’s disease according to following criteria: 
1. A follow up period of at least one year,
2. No response to medical treatment (diuretics, betahistine),
3. Unilateral hearing loss, with a good hearing in the opposite ear, 
4. Moderate or worse sensorineural hearing loss in the affected ear,
5. Dynamic patient with normal vision and no alcohol addiction (no 
age limits),
6. No drug allergies or idiosyncracy. 
Intratympanic Gentamicin Application
1. Direct injection method: We used commercially available genta-
micin 2 mL ampul (40 mgr/mL) (I.E. Uluagay, Turkey). Following sur-
face anesthesia, approximately 1 mL of buffered gentamicin solution 
(30.7 mg/mL) was injected directly into the middle ear using a 25-27 
G spinal needle when the patient was lying on his/her back, and his/
her head slightly turned towards the opposite side. The patient was 
asked not to gulp, and he/she stayed at this position for half an hour. 
This procedure was performed once a week, for three weeks. Pure 
tone audiogram was performed just before each gentamicin applica-
tion, and 3 doses were completed if there was no hearing loss. Treat-
ment was stopped when hearing loss appeared. A repeat caloric test 
was performed 2 weeks after completion of the treatment.  
2. Selective window method: In this procedure, the tympanomeatal 
flap was elevated under local anesthesia, and oval and round windows 
were examined. First, a piece of gel foam soaked in dexamethasone 
was placed on the round window until the level of the round win-
dow niche, then pieces of gel foam soaked in gentamicin (4 mg/mL) 
were placed on the oval window, all around the stapes footplate. 
Then, the tympanomeatal flap was put into place. Pure tone audiom-
etry and caloric test were repeated 3 months later. 
Statistical Analysis
Two groups were compared for mean low (250, 500, 1000, 2000 Hz ) 
and high (4000, 6000, 8000 Hz) frequency hearing thresholds, bither-
mal caloric test results, and vertigo control. Intergroup comparisons 
of the parametric variables were done with t test, and intergroup 
comparisons of the non-parametric variables were done with Mann 
Whitney U test. Intragroup pre- and post-procedure comparisons 
were done with Wilcoxon test. PASW (Statistical Package for the So-
cial Sciences version 18 Inc.; Chicago, IL, USA) program was used for 
statistical analysis. 
RESULTS
A total of 25 patients with definite Meniere’s disease, 13 females and 
12 males, were included in the study. The mean age of the study 
group was 47.8±10.7 years. Fifteen of 25 patients were administered 
IT gentamicin, and 10 of 25 had the selective window procedure. 
There were no differences between two groups for age, gender, the 
type of the hearing curve, mean follow up period, or caloric weak-
ness (p>0.05). The high frequency pure tone thresholds were better 
in the selective window procedure group (p<0.05) (Table 1). 
Pre- and post-treatment comparisons revealed that the mean low 
frequency threshold did not change, however there were significant 
increases in the mean high frequency threshold and caloric weak-
ness after treatment in IT gentamicin group (p<0.01). In selective 
window procedure group, only the increase in caloric weakness was 
significant (p<0.05) (Table 2). The number of patients that had hear-
Table 2. Intragroup comparisons of the pre- and post-treatment test results
IT gentamicin Before After Significance
Mean low-pitch hearing threshold (dB) 56.3±10.5 61.65±18.3 p>0.05
Mean high-pitch hearing threshold (dB) 59.05±17.4 69.4±21.98 p<0.01
Caloric weakness (%) 45.8±22.3 71.53±29.63 p<0.01
Selective window procedure Before  After  Significance
Mean low-pitch hearing threshold (dB) 51.6±7 52.2±5.6 p>0.05
Mean high-pitch hearing threshold (dB) 41.96±20.2 47.2±18.3 p>0.05
Caloric weakness (%) 37.6±23.9 54.6±30.6 p<0.05
IT: intratympanic; dB: decibel
Table 1. Pretreatment comparison of demographic characteristics and test 
results of two groups
 IT gentamicin Selective Significance
Age  47.8±12.6 48±7.5 p>0.05
Female / Male 9/6 4/6 p>0.05
Mean low-pitch hearing threshold (dB) 56.3±10.5 51.6±7 p>0.05
Mean high-pitch hearing threshold (dB) 59.05±17.4 41.96±20.2 p<0.05
Caloric weakness (%) 45.8±22.3 37.6±23.9 p>0.05
Follow up (months) 17.4±9.9 19.4±2.8 p>0.05
IT: intratympanic; dB: decibel
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ing loss more than 10 dB and a caloric weakness more than 50% was 
higher in the IT gentamicin group, but the difference between two 
groups was not significant (p>0.05) (Table 3).
The mean number of the injections was 2.4 (1-4) in IT gentamicin 
group. During follow up, vertigo recurred in 2 patients in IT gentami-
cin group, and one dose of IT gentamicin was administered to those 
patients. Vertigo attacks were also recurred in two patients who had 
selective window procedure. They had additional one dose of IT gen-
tamicin (Table 3).
There was no correlation of the number of injections with hearing 
loss or caloric weakness in the IT gentamicin group. 
DISCUSSION
Use of IT gentamicin or dexamethasone is an accepted treatment op-
tion in patients with Meniere’s disease that do not respond to medical 
treatment. IT gentamicin is more effective than IT dexamethasone for 
vertigo control [11].  However, its use is limited in patients with good 
hearing thresholds due to probability of hearing loss after treatment. 
IT gentamicin success is changing between 73-100% for vertigo con-
trol and results hearing loss between 0-75% of the patients according 
to the protocol used [7].
First, decreasing the frequency of application was tried in order to 
overcome this handicap. Probability of hearing loss is smaller in 
weekly applications [12]. As a matter of fact, recent protocols recom-
mended use of a single dose during vertigo attack (on demand) rath-
er than a standard regimen. The vertigo control rate was reported as 
96.5% without any hearing loss [13].
Controlling the place and the amount of the absorption of the 
drug is another option. A piece of gel foam soaked in gentamicin 
(26.7 mgr/mL) was put in front of the round window after clean-
ing this area, and vertigo control was reported as 75%, but hearing 
loss appeared in 10% of the patients [8]. On the opposite, the round 
window was protected with a piece of connective tissue, and then 
IT gentamicin (80 mg/mL) was administered twice a week [10]. This 
technique resulted in a vertigo control rate of 91%, and a hearing 
loss rate of 27%. Kalberg et al. [14] protected the round window with 
a piece of gel foam soaked in normal saline, and placed a piece of 
gel foam soaked in gentamicin (30 mg/mL) to the oval window. 
The vertigo control rate was found as 88% without any hearing 
loss. In our study, we used the same method, but we used dexa-
methasone. After a mean follow up period of 19 months, we found 
the vertigo control rate as 80%, and a high frequency hearing loss 
more than 10 dB was found only in 2 patients. When the mean of 
all frequencies was taken into consideration, there was 11 dB loss 
in one patient (10%) in selective window procedure group. How-
ever, 4 patients in direct injection group (26%) had more than 10 
dB hearing loss when the mean of all frequencies were taken into 
consideration.  
Some studies investigated the rate of absorption of the drugs into 
the inner ear through oval and round windows. Different drugs had 
different results [15, 16]. It was reported that application of gentamicin 
to oval window caused more vestibulotoxicity and hearing loss in 
Gunea pigs [17]. This was supposed to be due to more absorption 
of gentamicin through the oval window. Selective absorption has 
been confirmed by a number of studies.  King et al. [16] estimated 
that the rate of gadolinium absorption in the region of stapes was 
more than 90%. Salt et al. [15] showed that trimethylphenylammoni-
um (TMPA) marker was absorbed at a rate of 65% from the round 
window. Placing gentamicin to the oval window caused a mean in-
crease of 17±22.6 in the caloric weakness. However, this increase 
was found as 25.7±26.2 when gentamicin was administered direct-
ly to the middle ear. Less vestibulotoxicity in selective application 
shows that dexamethasone placed in round window not only pro-
tected the cochlear cells, but also the vestibular cells.  Application 
of gel foam soaked with drugs provides a longer stay of the drug in 
the middle ear, and access of the drug until the cochlear apex [18]. 
This situation seems to be true for the drugs placed to both win-
dows. 
Use of IT aminoglycosides and steroids is not new. Shea et al. [19] used 
IT  low-dose streptomycin/ high-dose dexamethasone mixture plus 
intravenous dexamethasone combination for 3 days in Meniere’s dis-
ease patients, and found the vertigo control rate as 88%, and hearing 
loss rate as  15.7%. It has been known that corticosteroids pass into 
the inner ear and attach to their own receptors. Those receptors have 
been shown predominantly in the spiral ligament, and then organ 
of Corti and stria vascularis in the human inner ear [20]. Ion homeo-
stasis, immune suppression, and free radical scavenging effects of 
those agents made them to be used to protect cochlea, particularly 
in ototoxic drug use and acoustic trauma [21]. The results of this study 
suggest that dexamathasone has a protective effect for gentamicin 
toxicity. 
In conclusion, applying dexamethasone and gentamicin simultane-
ously to different windows prevents vertigo at a high rate, and causes 
high frequency hearing loss only in only a small percent of the pa-
tients. Long term results of this promising treatment option should 
be obtained to determine whether it could take place in the treat-
ment protocol of Meniere’s disease.  
Ethics Committee Approval: Ethics committee approval was received for this 
study from the ethics committee of Pamukkale University School of Medicine 
(No:60116787-020/37).
Table 3. Number (n) of patients classified according to level of hearing loss 
or caloric weakness after treatment
 IT Gentamicin Selective Significance
n of patients who had more than  4/1 0/1 p>0.05 
10 dB low pitch difference  
(Decreased / Increased)
n of patients who had more than  6/0 2/1 p>0.05 
10 dB high pitch difference  
(Decreased/ Increased) 
% of patients who had 10-20% 13% 10% p>0.05 
caloric decrease
% of patients who had 20-50%  27% 40% p>0.05 
caloric decrease
% of patients who had more than  27% 10% p>0.05 
50% caloric decrease
n of patient with recurrence  2 (13%) 2 (20%) p>0.05 
of vertigo attack
IT: intratympanic; dB: decibel
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